Novartis

Novartis

Verified
To discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering.

Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$231.8b (Public information from Jun 2024)
Company register number CHE-106.054.058
Basel Canton of Basel-Stadt (HQ)
Corporate Venture Fund: dRx Capital, Novartis Venture Fund

Financials

Estimates*

Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues49.9b52.9b51.8b46.7b48.8b50.6b51.1b
% growth3 %6 %(2 %)(10 %)5 %4 %1 %
EBITDA17.2b33.1b16.4b18.5b19.3b20.5b20.9b
% EBITDA margin34 %63 %32 %40 %40 %40 %41 %
Profit8.1b24.0b7.0b14.9b10.2b11.9b12.8b
% profit margin16 %45 %13 %32 %21 %24 %25 %
EV / revenue4.8x3.9x3.9x4.7x4.3x4.1x4.0x
EV / EBITDA14.0x6.2x12.4x11.9x10.9x10.2x9.8x
R&D budget9.0b9.5b10.0b11.4b---
R&D % of revenue18 %18 %19 %24 %---

Source: Dealroom estimates

  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO

$6.5m

Grant
Total Funding$6.5m

Recent News about Novartis

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Ziarco Pharma
ACQUISITION by Novartis Dec 2016
Encore Vision Inc.
ACQUISITION by Novartis Dec 2016
Corthera
ACQUISITION by Novartis Dec 2009
SomaLogic
exited
The Medicines Company
ACQUISITION by Novartis Nov 2019
Endocyte
ACQUISITION by Novartis Nov 2018
View 207 more